No significant difference was seen on cancer-specific survival in CRC in relation to the NOS2/CD163 ratio, neither in all CRC cases (Figure 4A) nor in the selected group of potentially curatively resected colon cancers (Figure 4B). This evidence concerns the gene NOS2 and colonic neoplasm.